Is Halozyme Therapeutics Inc (HALO) overvalued? · P/E 15, rev $857.7M
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
This page asks whether Halozyme Therapeutics Inc (HALO) looks expensive on cached numbers — not a short thesis.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
HALO currently screens at market cap $7.10B and trailing P/E 15.3. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next HALO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the HALO stock page for the full model, not this heading.
Not investment advice.